Duval/CIBMTR Score for AML Survival

Estimates post–allogeneic transplant survival in AML using five adverse pre‑transplant clinical risk factors.

Disease group
Primary induction failure or duration of first complete remission > 6 months0Duration of first complete remission < 6 months+1
Cytogenetics prior to HSCT
Good or intermediate0Poor+1
HLA match group
HLA identical sibling or well matched or partially matched unrelated0Mismatched unrelated+1Related other than HLA identical sibling+2
Circulating blasts (at time of transplant)
Absent0Present+1
Karnofsky or Lansky scale
90-1000< 90+1
Karnofsky or Lansky scale
90-1000< 90+1

Indications for Use

Used for adults with AML undergoing allogeneic HCT in relapse or primary induction failure to estimate post‑transplant overall survival based on five adverse pre‑HCT factors (CR1 duration <6 months, circulating blasts, non–HLA‑identical sibling donor, Karnofsky <90, adverse cytogenetics) derived from a large CIBMTR registry study. Predicts 3‑year OS ranging from 42% (score 0) to 6% (score ≥3) 1 [Level II evidence].

Insights & Cautions

Stratifies relapse/PIF AML before allo‑HCT using five adverse factors (CR1 <6 mo, circulating blasts, non‑sibling donor, Karnofsky <90, adverse cytogenetics). Three‑year OS declines from 42% (score 0) to 6% (≥3) 1 [Level II evidence].
Cautions: underestimates molecular risk (e.g., TP53, MK), was built in retrospective cohorts, and performance is lower in modern transplant platforms; use only as broad prognostic guidance, not for individual prediction.